Why choose TREMFYA®?
In clinical trials of patients who received TREMFYA® IV initial and SC maintenance dosing, TREMFYA® helped patients achieve:
FAST ACTING
Rapid symptom relief†
at 4 weeks
and clinical remission
at week 12.
†Symptom relief is based on fewer bowel movements and less rectal bleeding (bloody stools) observed as early as week 4.
LONG LASTING
Clinical remission at
1 year.‡
‡TREMFYA® patients who met clinical response at 12 weeks.
VISIBLE REPAIR
OF THE INTESTINAL LINING
OF THE INTESTINAL LINING
Endoscopic remission
at 1 year.§ǁ
§Visually assessed areas may
not represent remission of the
entire colon lining.
ǁTREMFYA® patients who met
clinical response at 12 weeks.
AT 2 YEARS,
AT 2 YEARS,
patients were in clinical remission.¶
¶In UC, results at 1 and 2 years were measured in TREMFYA® patients who met clinical response at 12 weeks. After 1 year, patients and doctors knew TREMFYA® was used. This may have influenced results.
Results may vary.
Talk to your healthcare provider to
see if TREMFYA® is right for you.
TREMFYA® is the only IL-23 blocker for UC to offer self-administration from the start
You and your healthcare provider will discuss how you start TREMFYA® for UC:
Subcutaneous (SC) injections under the skin following training*
OR
IV infusions through
a vein in the arm
*If your healthcare provider decides that you or a caregiver may be able to give your injections of TREMFYA® at home, you should receive training on the right way to prepare and inject TREMFYA®. Do not try to inject yourself until you have been trained by your healthcare provider.
IL=interleukin.
